- Home
- FOLD vs SWTX Comparison
FOLD vs SWTX Comparison
Compare FOLD & SWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- SWTX
- Stock Information
- Founded
- FOLD 2002
- SWTX 2017
- Country
- FOLD United States
- SWTX United States
- Employees
- FOLD N/A
- SWTX N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- SWTX Biotechnology: Pharmaceutical Preparations
- Sector
- FOLD Health Care
- SWTX Health Care
- Exchange
- FOLD Nasdaq
- SWTX Nasdaq
- Market Cap
- FOLD 2.8B
- SWTX 2.8B
- IPO Year
- FOLD 2007
- SWTX 2019
- Fundamental
- Price
- FOLD $9.58
- SWTX $34.87
- Analyst Decision
- FOLD Strong Buy
- SWTX Strong Buy
- Analyst Count
- FOLD 8
- SWTX 6
- Target Price
- FOLD $17.00
- SWTX $68.83
- AVG Volume (30 Days)
- FOLD 2.1M
- SWTX 1.5M
- Earning Date
- FOLD 02-26-2025
- SWTX 02-25-2025
- Dividend Yield
- FOLD N/A
- SWTX N/A
- EPS Growth
- FOLD N/A
- SWTX N/A
- EPS
- FOLD N/A
- SWTX N/A
- Revenue
- FOLD $493,671,000.00
- SWTX $135,487,000.00
- Revenue This Year
- FOLD $34.33
- SWTX $3,410.19
- Revenue Next Year
- FOLD $21.70
- SWTX $86.06
- P/E Ratio
- FOLD N/A
- SWTX N/A
- Revenue Growth
- FOLD 32.58
- SWTX N/A
- 52 Week Low
- FOLD $8.79
- SWTX $28.21
- 52 Week High
- FOLD $14.03
- SWTX $53.92
- Technical
- Relative Strength Index (RSI)
- FOLD 50.06
- SWTX 45.09
- Support Level
- FOLD $8.79
- SWTX $31.96
- Resistance Level
- FOLD $9.63
- SWTX $37.59
- Average True Range (ATR)
- FOLD 0.29
- SWTX 3.33
- MACD
- FOLD 0.05
- SWTX -0.35
- Stochastic Oscillator
- FOLD 90.48
- SWTX 22.12
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.